Effect of Essential Oils as Adjutants on the Treatment of Subjects With Periodontitis: Assessment of Metabolic Variables as Effect Modifiers
Periodontitis, an infectious disease that affects the tooth-supporting tissues and shows a wide range of clinical, microbiological, and immunological manifestations, is associated with and probably caused by dynamic interaction among infectious agents, host immune responses, hazardous environmental exposure and genetic propensity. Bacteria are necessary for the disease to appear, but are not sufficient and do not account for all cases of periodontitis. According to one survey in the USA, chronic periodontitis affects approximately 46% of the adult population, with an even higher prevalence among the elderly. This prevalence refers to the cohort of young adults according to the WHO, with ages ranging from 35 to 44 years. Forms of periodontitis that appear at younger ages (before the age of 30 years), and that have other characteristics in addition to age, are known as aggressive periodontitis. The prevalence of this disorder ranges from 0.2% in Caucasians to 2.6% in Afro-Americans. The microbiota of the human oral mucosa together with other anatomical locations in the body constitute the human microbiome. The equilibrium between these organisms and the host response plays a fundamental role in human biology, both in health maintenance and in the appearance of disease. Unfavorable alterations in the composition of the microbiota are termed dysbiosis.
Antiseptics and antibiotics such as Chlorhexidine or Metronidazole, are delivered locally as an adjunct to scaling and root planing procedures, in order to eradicate the subgingival microbes, hence creating a healthy subgingival environment. However, the results presented in the literature are inconclusive. There is a need for further clinical trials with strict methodological criteria for allowing a more precise assessment of the efficacy of local antimicrobials in the treatment of chronic periodontitis.
Recently, there has been renewed interest in the application of natural products. Several natural products and herbs have claimed to have better properties and less side effects than chemical agents for irrigation. The use of natural extracts and essential oils as an irrigation agent for ultrasonic instrumentation has shown to promote slight adjunctive effect compared to chlorhexidine or water. In other study, natural extract showed a greater improvement compared to controls in patients with a more severe degree of periodontitis. However, in other studies this pocket reduction and clinical attachment gain were no significant when compared to water. Natural products have also been tested in forms of oral spray, and have shown to be effective against common oral pathogens without significant cytotoxicity in an in vitro study. Thus, it has the potential to prevent the infections and may serve as adjunctive treatment to conventional therapy. They claim to have the same or even more anti-microbial effect and anti-inflammatory effect without adding any chemicals. But still there is no adequate scientific evidence to support this hypothesis.
This study aims to test the effect as an adjutant to therapy of a nutraceutical composed of several plant extracts in patients with periodontitis and different levels of risk for metabolic syndrome. Specifically:
- The response of periodontal clinical variables to non-surgical periodontal treatment in patients treated with the extract, compared to controls.
- The effect on local inflammatory markers, in patients treated with the extract compared to controls.
- The modifier effect of metabolic syndrome-related variables in the treatment outcomes of the patients treated with the extract compared to controls.
Hypothesis:
The application of the plant extract would act as an anti-inflammatory agent, contributing to better treatment outcomes of periodontitis, in terms of clinical and biochemical variables.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
METHODOLOGY
Study design Randomized, controlled, double-blinded clinical trial.
Study unit/population Subjects with diagnosis of periodontitis according to the joint EFP/AAP 2018 criteria for the case definition of periodontitis.
Inclusion criteria Patients attended in the University of Granada School of Dentistry (Granada, Spain) Signing of a written consent.
Exclusion criteria Age under 18 years, received periodontal treatment in the last year, anti-microbial therapy in the previous 3 months, multiple pregnancy and the presence of neoplastic or severe infectious diseases.
Sampling and randomization It is estimated to explore at least 60 patients, of which 30 will be randomized to each group, accordingly to similar studies on the topic available in the literature. The group allocation will also follow similar studies published previously in the field (7-9, 12, 13). All patients will receive standard periodontal treatment with an ultrasonic new generation device (AIRFLOW® Prophylaxis Master, EMS Dental, Nyon, Switzerland), and the group division will be based on the use of the extract as an adjunct to non-surgical treatment.
Test group: Patients that will receive the application of the extract in form of irrigation solutions in the periodontal pockets during regular periodontal treatment. Patients would continue at home during the follow-up period, taking the essential oils in as a rinse twice per day, and as a spray when regular toothbrush could not be performed.
Control group: Patients that will follow the same protocol, but using regular irrigation and a placebo spray at home.
The researchers that will perform the clinical examinations will be blinded for the group allocation of the participants, since the random allocation and prescription will be performed by a different researcher. Study products and placebo will be provided previously by the company BIONAP.
Study variables
- Sociodemographic variables: sex, age, smoking habit (cigs/day), alcohol consumption (g/day).
Periodontal clinical variables:
Periodontal examination will be performed by a calibrated researcher using PCPUNC15 periodontal probe (Hu-friedy, Chicago, IL, USA) and dental exploration mirror. Six surfaces in each implant will be measured: mesiovestibular, vestibular, distovestibular, distolingual, lingual, mesiolingual. All clinical data will be recorded in a periodontal chart. Clinical data will be gathered at baseline, and at 2 and 6 months of follow-up.
Bleeding on probing: The percentage of bleeding implants while probing, will the registered following the index of Ainamo and Bay (14).
Oral hygiene: Oral hygiene will be measured using the Plaque Index proposed by Tonetti (15). The presence of plaque will be registered by visual examination without using a plaque revealing agent.
Metabolic syndrome-related variables:
- Body weight
- Body height
- Body mass index
- Waist circumference
- Blood pressure
- Biochemical variables:
Samples of saliva, subgingival plaque and gingival crevicular fluid will be obtained at the beginning of the study, at 2 months and at the end of follow-up. A panel of inflammatory cytokines will be assessed.
Blood samples will be obtained at the beginning of the study, at 2 months and at the end of follow-up for the assessment of:
- Fasting blood glucose
- Lipid profile (Total cholesterol, Triglycerides, LDL-cholesterol and HDL-cholesterol).
Data management and statistical analysis A database in Excel format will be prepared including all recorded variables. The data will be analyzed by a single researcher. The statistical software SPSS v.21.0 (IBM Inc., Chicago, IL, USA) will be used, performing descriptive statistics (means, standard deviations and percentages) and analytical procedures (95% confidence intervals, Mann-Whitney test, Chi-square, Student's t-test for paired samples, and univariate and multivariate regression analysis). A 5% significance level will be considered for all tests.
ETHICAL CONSIDERATIONS The study will be designed in order to comply with the standards of the las revision of the Helsinki declaration. Approval from the Research Ethics Committee in Human Studies of the University of Granada will be obtained prior to the beginning of the study. Written informed consent will be obtained from all participants in the study. All obtained data will be anonymous and the study will be designed following the CONSORT guidelines for reporting clinical trials (16).
WORK PLAN
The project has been planned to be performed in a period of 2 years:
- Study registration, ethical approval, and planning: December 2018 - February 2019.
- Study enrollment, allocation, samples and data gathering. Follow-up period: March 2019 - April 2020.
- Statistical analysis of all data: June 2020 - September 2020.
- Manuscript preparation and publication process: October 2020 - April 2021.
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
-
Granada, Espanha, 18071
- University of Granada School of Dentistry
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Patients attended in the University of Granada School of Dentistry (Granada, Spain)
- Accepting to be enrolled in the study and signing of a written consent.
Exclusion Criteria:
- Age under 18 years,
- Received periodontal treatment in the last year,
- Anti-microbial therapy in the previous 3 months
- Allergies
- Multiple pregnancy
- Presence of neoplastic or severe infectious diseases.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Test Group
Patients that will receive the application of the extract in form of irrigation solutions in the periodontal pockets during regular periodontal treatment.
Patients would continue at home during the follow-up period, taking the essential oils in as a rinse twice per day, and as a spray when regular toothbrush could not be performed.
|
Oral rinse enriched with plant-based essential oils.
|
|
Comparador de Placebo: Control Group
Patients that will follow the same protocol, but using placebo irrigation and a placebo spray at home.
|
Oral rinse with the exact characteristics in terms of colour and odour of the plant-based one, but without the essential oils aimed to test in this study
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Pocket probing depth
Prazo: Change from Baseline Pocket probing depth at 3 months
|
Depth of periodontal pockets present in the teeth of each patient in millimeters (mm) using a periodontal probe (PCPUNC-15)
|
Change from Baseline Pocket probing depth at 3 months
|
|
Pocket probing depth
Prazo: Change from Baseline Pocket probing depth at 6 months
|
Depth of periodontal pockets present in the teeth of each patient in millimeters (mm) using a periodontal probe (PCPUNC-15)
|
Change from Baseline Pocket probing depth at 6 months
|
|
Gingival recession
Prazo: Change from Baseline Gingival recession at 3 months
|
Distance from the gingival margin to the cemento-enamel junction in the teeth of each patient in millimeters (mm) using a periodontal probe (PCPUNC-15)
|
Change from Baseline Gingival recession at 3 months
|
|
Gingival recession
Prazo: Change from Baseline Gingival recession at 6 months
|
Distance from the gingival margin to the cemento-enamel junction in the teeth of each patient in millimeters (mm) using a periodontal probe (PCPUNC-15)
|
Change from Baseline Gingival recession at 6 months
|
|
Bleeding on probing
Prazo: Change from Baseline Bleeding on probing at 3 months
|
Percentage of teeth (%) that showed bleeding during periodontal examination.
|
Change from Baseline Bleeding on probing at 3 months
|
|
Bleeding on probing
Prazo: Change from Baseline Bleeding on probing at 6 months
|
Percentage of teeth (%) that showed bleeding during periodontal examination.
|
Change from Baseline Bleeding on probing at 6 months
|
|
Oral hygiene
Prazo: Change from Baseline Visual Plaque Index at 3 months
|
Percentage of teeth surfaces (4 in each tooth) that showed visible plaque during periodontal examination (Visual Plaque Index).
|
Change from Baseline Visual Plaque Index at 3 months
|
|
Oral hygiene
Prazo: Change from Baseline Visual Plaque Index at 6 months
|
Percentage of teeth surfaces (4 in each tooth) that showed visible plaque during periodontal examination (Visual Plaque Index).
|
Change from Baseline Visual Plaque Index at 6 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Body weight
Prazo: Change from Baseline Body weight at 3 months
|
Weight of each patient in kilograms (Kg) with a body scale.
|
Change from Baseline Body weight at 3 months
|
|
Body weight
Prazo: Change from Baseline Body weight at 6 months
|
Weight of each patient in kilograms (Kg) with a body scale.
|
Change from Baseline Body weight at 6 months
|
|
Body height
Prazo: Baseline
|
Height of each patient in centimeters (cm) with a scale.
|
Baseline
|
|
Waist circumference
Prazo: Change from Baseline Waist circumference at 3 months
|
Waist abdominal circumference of each patient in centimeters (cm) with a measure tape.
|
Change from Baseline Waist circumference at 3 months
|
|
Waist circumference
Prazo: Change from Baseline Waist circumference at 6 months
|
Waist abdominal circumference of each patient in centimeters (cm) with a measure tape.
|
Change from Baseline Waist circumference at 6 months
|
|
Systolic Blood pressure
Prazo: Change from Baseline Systolic Blood pressure at 3 months
|
Systolic Blood pressure of each patient in Hg millimeters (Hg mm) measured with a sphygmomanometer.
|
Change from Baseline Systolic Blood pressure at 3 months
|
|
Systolic Blood pressure
Prazo: Change from Baseline Systolic Blood pressure at 6 months
|
Systolic Blood pressure of each patient in Hg millimeters (Hg mm) measured with a sphygmomanometer.
|
Change from Baseline Systolic Blood pressure at 6 months
|
|
Diastolic Blood pressure
Prazo: Change from Baseline Diastolic Blood pressure at 3 months
|
Diastolic Blood pressure of each patient in Hg millimeters (Hg mm) measured with a sphygmomanometer.
|
Change from Baseline Diastolic Blood pressure at 3 months
|
|
Diastolic Blood pressure
Prazo: Change from Baseline Diastolic Blood pressure at 6 months
|
Diastolic Blood pressure of each patient in Hg millimeters (Hg mm) measured with a sphygmomanometer.
|
Change from Baseline Diastolic Blood pressure at 6 months
|
|
Glycemia
Prazo: Change from Baseline Glycemia at 3 months
|
Fasting glycemia of each patient in milligrams per deciliter (mg/dL) measured with a glucometer.
|
Change from Baseline Glycemia at 3 months
|
|
Glycemia
Prazo: Change from Baseline Glycemia at 6 months
|
Fasting glycemia of each patient in milligrams per deciliter (mg/dL) measured with a glucometer.
|
Change from Baseline Glycemia at 6 months
|
|
Total cholesterol
Prazo: Change from Baseline Total cholesterol at 6 months
|
Total cholesterol levels of each patient in mg/dL measured in serum samples.
|
Change from Baseline Total cholesterol at 6 months
|
|
Triglyceride
Prazo: Change from Baseline Triglyceride at 6 months
|
Triglyceride levels of each patient in mg/dL measured in serum samples.
|
Change from Baseline Triglyceride at 6 months
|
|
LDL-cholesterol
Prazo: Change from Baseline LDL-cholesterol at 6 months
|
Low-density lipoprotein levels of each patient in mg/dL measured in serum samples.
|
Change from Baseline LDL-cholesterol at 6 months
|
|
HDL-cholesterol
Prazo: Change from Baseline HDL-cholesterol at 6 months
|
High-density lipoprotein cholesterol levels of each patient in mg/dL measured in serum samples.
|
Change from Baseline HDL-cholesterol at 6 months
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Sex
Prazo: Baseline
|
Sex of the patient (male/female)
|
Baseline
|
|
Age
Prazo: Baseline
|
Age of the patient at baseline examination
|
Baseline
|
|
Smoking
Prazo: Baseline
|
Smoking habit of each patient in cigarrettes per day.
|
Baseline
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Francisco Mesa, PhD, Full Professor
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- PON-FSE-2017-1
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .